Aurora Cannabis partner signs distribution deal in Australia

Aurora Cannabis partner signs distribution deal in Australia

Cann Group to hit the ground running as soon as the first products arrive

A leading medicinal cannabis company in Australia, and a primary partner of Aurora Cannabis (TSE: ACB), is ready to start distributing cannabis products. A deal with healthcare services and products supplier Symbion has been struck, which also involves Aurora and its tetrahydrocannabinol (THC) oil. Cann Group is ready to hit the ground running.

The partnership between Cann Group and Symbion gives over 4,000 retail pharmacies and 1,300 Australian hospitals access to new cannabis products, all of which will be exposed to the imported products designed to provide solutions for Special Access Scheme (SAS) patients. Import and supply permits are already in place for another five products, which will be supplied by Aurora.

Peter Crock, Cann Group’s CEO, said in a statement, “We are now operating our existing Southern and Northern production facilities at full capacity, with in excess of 40 harvests now completed, and we are advancing our product manufacturing capabilities with IDT Australia. The Victorian Government acknowledged the progress made in the development of local industry capabilities when it announced recently the Government’s decision to cease its manufacturing role.”

Crock has been leading Cann Group since 2016 and he also serves as the chairman of the Medicinal Cannabis Industry Australia (MCIA). He adds that the company’s progression toward the supply of commercial products demonstrates an important step for the company, as well as the entire Australian health industry.

He adds, “Cann’s development and production expertise – together with the specialist manufacturing capabilities provided by our partner, IDT Australia – ensures Australian patients will have access to high quality and safe medicinal cannabis products.

“We are well underway with our major expansion program near Mildura, which is expected to be commissioned towards the end of next calendar year, and should consolidate Cann’s position as the leading local producer, with ample capacity to meet local patient needs.”

Australia is fourth on the list of countries with the most licenses for cannabis sales. It is also third in the number of pharmaceutical cannabis trademarks.